Sunday, February 9, 2025

CATEGORY

Clinical Researches

Otsuka Secures Global Licensing for FUS-ALS Treatment from Ionis

Otsuka Pharmaceutical Co., Ltd. has entered an exclusive worldwide licensing agreement with Ionis Pharmaceuticals to develop and market ulefnersen (ION363), a promising drug candidate...

Orion’s Virtakoivu Advances Cancer Treatment Through Immune Activation

Key TakeawaysImmunotherapy can provide long-lasting responses for specific cancer types, such as metastatic melanoma and lung cancer. Combining immunotherapy with other treatments may...

Texas Launches Innovative HPV Self-Screening Pilot to Boost Cervical Cancer Detection

Key Takeaways:Self-collection offers a convenient and private screening option, potentially increasing participation rates. The pilot program addresses significant barriers such as lack of...

Jazz Pharma Secures FDA Nod for Ziihera in HER2+ Biliary Tract Cancer

Key TakeawaysProvides a new, targeted treatment option for patients with limited alternatives. Highlights the growing role of bispecific antibodies in cancer therapy. Positions...

Early Colon Cancer Screening Lacks Clear Protocols for High-Risk Under-50s

Determining the benefits and risks of colorectal cancer (CRC) screening for individuals under 50 with a family history remains unresolved. Recent findings highlight significant...

Johnson & Johnson Highlights Expansive Hematology Innovations at ASH 2024

Johnson & Johnson is set to unveil an extensive range of over 90 research abstracts at the 2024 American Society of Hematology Annual Meeting...

Abbott Boosts Clinical Trial Diversity Through Strategic Partnerships and New Initiatives

parnABBOTT PARK, Ill. – In its third year, Abbott has intensified efforts to diversify clinical trials by releasing 'Advancing Diversity in Clinical Trials,' a...

Dapirolizumab Pegol Boosts Lupus Treatment Efficacy in Phase 3 Study

Key TakeawaysDZP achieved a 14.6% higher BICLA response rate at 48 weeks compared to SOC alone. Participants on DZP experienced a 50% reduction...

J&J Introduces Yuvanci Tablets to Combat Pulmonary Hypertension

Johnson & Johnson has officially launched its latest pharmaceutical offering, Yuvanci Combination Tablets, aimed at treating patients with pulmonary arterial hypertension (PAH). This new...

Melt Pharmaceuticals Achieves Successful Phase 3 Results for MELT-300 in Cataract Surgery Sedation

Melt Pharmaceuticals announced that its lead product candidate, MELT-300, has demonstrated significant efficacy and safety in a pivotal Phase 3 clinical trial. The non-IV,...

GSK’s Linerixibat Significantly Reduces Itching in PBC Patients in Phase III Trial

GSK plc unveiled promising results from its Phase III GLISTEN trial, showcasing linerixibat's effectiveness in alleviating chronic itching among individuals with primary biliary cholangitis...

Pliant Therapies Unveils Promising PSC Treatment Results at Liver Meeting 2024

Key takeawaysBexotegrast shows significant potential in reducing liver fibrosis and improving biochemical markers in PSC patients. The drug's favorable safety profile across various...

FDA Seeks Labeling Clarifications Before Approving IZERVAY’s Supplemental Application

Key TakeawaysAstellas aims to incorporate positive two-year data from the GATHER2 Phase 3 trial into IZERVAY’s U.S. prescribing information. The FDA’s focus on...

Incyte Pauses Phase 2 MRGPRX2 Trial After Toxicity Concerns

Key TakeawaysIncyte may redirect resources towards alternative therapeutic candidates to maintain its research momentum. The collaboration with the FDA underscores Incyte's commitment to...

Icotrokinra Delivers Superior Skin Clearance in Phase 3 Psoriasis Study

Johnson & Johnson has announced groundbreaking Phase 3 results for icotrokinra (JNJ-2113), showcasing remarkable skin clearance in patients suffering from moderate to severe plaque...

Latest news